Pivotal Therapeutics (PVTTF) 0.0010 $PVTTF IIRO
Post# of 273254
Posted On: 09/20/2016 5:15:31 AM
Pivotal Therapeutics (PVTTF) 0.0010 $PVTTF
IIROC Trading Halt - PVO
CNW Group - Thu May 05, 7:25AM CDT
The following issues have been halted by IIROC:
Pivotal Therapeutics Announces Issuance of US Patent 9,248,138 for the Stabilization of Vulnerable Plaque Utilizing a Combination of Statin and Omega 3 Fatty Acids
TheNewswire.ca - Tue Feb 02, 4:36PM CST
(via Thenewswire.ca)
Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes
TheNewswire.ca - Mon Jan 04, 8:28PM CST
(via Thenewswire.ca)
Pivotal Therapeutics Announces Third Quarter Financial Results and Executes Distribution Agreement
TheNewswire.ca - Mon Nov 30, 11:43AM CST
(via Thenewswire.ca)
BeneFishial(TM) Pet Formulation Approved For Sale - The First in Pivotal's Animal Health and Nutrition Line
TheNewswire.ca - Wed Nov 25, 4:46PM CST
(via Thenewswire.ca)
Pivotal Announces Publication Evaluating 171 Over-the-Counter (OTC) Omega-3 Nutritional Supplements - 50% of the OTC Products Failed at Least one of the Oxidative Safety Limits
TheNewswire.ca - Fri Nov 06, 2:12PM CST
(via Thenewswire.ca)
Pivotal Receives Notice of Allowance for U.S. Application 14/594,095 for the Stabilization of Vulnerable Plaque Utilizing a Combination of Statin and PVT-100
TheNewswire.ca - Thu Oct 08, 2:36PM CDT
(via Thenewswire.ca)
Pivotal Therapeutics Announces Issuance of U.S. Patent 9,119,826 for a Kit that Includes Vascazen(tm) and an Omega-3 Fatty Acid Diagnostic Asssay for the Dietary Management of Cardiovascular Patients Deficient in Omega-3
TheNewswire.ca - Tue Sep 22, 6:00AM CDT
(via Thenewswire.ca)
Pivotal Therapeutics Announces Second Quarter Financial Results
TheNewswire.ca - Fri Aug 28, 8:52PM CDT
(via Thenewswire.ca)
First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100
CNW Group - Thu Jun 04, 1:25PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today the enrollment of the first patient in Pivotal's POMEGA Phase IIa clinical trial with PVT-100.
Pivotal Therapeutics Announces First Quarter Financial Results
PR Newswire - Mon Jun 01, 8:19PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2015. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel
PR Newswire - Mon May 11, 2:17PM CDT
Pivotal Therapeutics Inc. (CSE
VO; OTCQX VTTF), ("Pivotal" or the "Company"
, a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today the company and Mrs. Rachelle MacSweeney, Co-Founder, President and COO will be featured on CEO Clips on CBC's The Documentary Channel. CEO Clips, a series which profiles the most innovative publicly traded companies in North America, will feature Pivotal on The Documentary Channel beginning May 11, 2015, Monday through Friday, throughout the day and evenings. It can also be viewed online via this link: http://www.b-tv.com/pivotal-therapeutics-ceo-clip/.
Pivotal Therapeutics Announces 2014 Financial Results
PR Newswire - Thu Apr 30, 8:20PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the fiscal year ended December 31, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal receives Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and support cardiovascular health and normal triglyceride levels
PR Newswire - Mon Apr 27, 11:48AM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it received Health Canada approval to expand the indication of OMAZEN®'s product line specifically for cardiovascular health. The Natural and Non-Prescription Health Products Directorate of Health Canada (NNHPD) issued Natural Product Number (NPN) NPN 80060196 with the claim that helps to maintain and support cardiovascular health and NPN 80060197 with the claim helps to support and maintain normal serum/blood triglycerides/triacylglycerol levels. These new products contain the same unique formulation and high purity as OMAZEN® and will also be positioned for the professional market such as Wellness Clinics, Cardiac Rehabilitation Clinics, Sports Medicine Clinics and Private Executive Healthcare Clinics.
IIROC Trading Halt - PVO
CNW Group - Thu May 05, 7:25AM CDT
The following issues have been halted by IIROC:
Pivotal Therapeutics Announces Issuance of US Patent 9,248,138 for the Stabilization of Vulnerable Plaque Utilizing a Combination of Statin and Omega 3 Fatty Acids
TheNewswire.ca - Tue Feb 02, 4:36PM CST
(via Thenewswire.ca)
Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes
TheNewswire.ca - Mon Jan 04, 8:28PM CST
(via Thenewswire.ca)
Pivotal Therapeutics Announces Third Quarter Financial Results and Executes Distribution Agreement
TheNewswire.ca - Mon Nov 30, 11:43AM CST
(via Thenewswire.ca)
BeneFishial(TM) Pet Formulation Approved For Sale - The First in Pivotal's Animal Health and Nutrition Line
TheNewswire.ca - Wed Nov 25, 4:46PM CST
(via Thenewswire.ca)
Pivotal Announces Publication Evaluating 171 Over-the-Counter (OTC) Omega-3 Nutritional Supplements - 50% of the OTC Products Failed at Least one of the Oxidative Safety Limits
TheNewswire.ca - Fri Nov 06, 2:12PM CST
(via Thenewswire.ca)
Pivotal Receives Notice of Allowance for U.S. Application 14/594,095 for the Stabilization of Vulnerable Plaque Utilizing a Combination of Statin and PVT-100
TheNewswire.ca - Thu Oct 08, 2:36PM CDT
(via Thenewswire.ca)
Pivotal Therapeutics Announces Issuance of U.S. Patent 9,119,826 for a Kit that Includes Vascazen(tm) and an Omega-3 Fatty Acid Diagnostic Asssay for the Dietary Management of Cardiovascular Patients Deficient in Omega-3
TheNewswire.ca - Tue Sep 22, 6:00AM CDT
(via Thenewswire.ca)
Pivotal Therapeutics Announces Second Quarter Financial Results
TheNewswire.ca - Fri Aug 28, 8:52PM CDT
(via Thenewswire.ca)
First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100
CNW Group - Thu Jun 04, 1:25PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today the enrollment of the first patient in Pivotal's POMEGA Phase IIa clinical trial with PVT-100.
Pivotal Therapeutics Announces First Quarter Financial Results
PR Newswire - Mon Jun 01, 8:19PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2015. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel
PR Newswire - Mon May 11, 2:17PM CDT
Pivotal Therapeutics Inc. (CSE
VO; OTCQX VTTF), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today the company and Mrs. Rachelle MacSweeney, Co-Founder, President and COO will be featured on CEO Clips on CBC's The Documentary Channel. CEO Clips, a series which profiles the most innovative publicly traded companies in North America, will feature Pivotal on The Documentary Channel beginning May 11, 2015, Monday through Friday, throughout the day and evenings. It can also be viewed online via this link: http://www.b-tv.com/pivotal-therapeutics-ceo-clip/. Pivotal Therapeutics Announces 2014 Financial Results
PR Newswire - Thu Apr 30, 8:20PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the fiscal year ended December 31, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal receives Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and support cardiovascular health and normal triglyceride levels
PR Newswire - Mon Apr 27, 11:48AM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it received Health Canada approval to expand the indication of OMAZEN®'s product line specifically for cardiovascular health. The Natural and Non-Prescription Health Products Directorate of Health Canada (NNHPD) issued Natural Product Number (NPN) NPN 80060196 with the claim that helps to maintain and support cardiovascular health and NPN 80060197 with the claim helps to support and maintain normal serum/blood triglycerides/triacylglycerol levels. These new products contain the same unique formulation and high purity as OMAZEN® and will also be positioned for the professional market such as Wellness Clinics, Cardiac Rehabilitation Clinics, Sports Medicine Clinics and Private Executive Healthcare Clinics. 
(0)
(0)Scroll down for more posts ▼